Home

arrow iconNewsarrow iconarrow icon

ESHRE 2025 Delivers Breakthrough Research in Reproductive Medicine

ESHRE 2025 Delivers Breakthrough Research in Reproductive Medicine

The ESHRE 2025 Annual Meeting in Paris highlighted advancements in reproductive medicine, covering the psychological effects of pregnancy loss, AI's role in enhancing IVF predictions, and the resilience of 2S/LGBTQIA+ couples. It also introduced the T'easy AI platform for sperm detection and discussed preimplantation genetic testing benefits for older women.

By FertilityIn

08 Dec 2025

6 min read

ESHRE 2025

ESHRE 2025

ESHRE 2025 Delivers Breakthrough Research in Reproductive Medicine

The 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Paris, France, has unveiled significant advances across reproductive medicine, from artificial intelligence applications to psychological support needs, offering new hope and enhanced treatment approaches for fertility patients worldwide.



Mental Health Impact of Pregnancy Loss Affects Both Partners

A comprehensive prospective study led by Astrid Marie Kolte from Copenhagen University Hospitals and Hvidovre Hospital in Denmark has illuminated the substantial psychological burden of pregnancy loss on both women and their partners. The four-year study tracked over 2,000 women and 1,200 partners, assessing mental health symptoms within 2–8 weeks following a pregnancy loss.



The findings reveal concerning levels of psychological distress among women experiencing pregnancy loss: 49.4% reported elevated stress, 24.1% experienced moderate-to-severe anxiety, and 12.2% met criteria for moderate-to-severe depression. Partners faced significant challenges as well, with 23.6% reporting stress, 8.3% experiencing anxiety, and 3.8% developing depression.



The research identified critical risk factors, including prior pregnancy losses and insufficient primary treatment, both strongly linked to worse mental health outcomes. Conversely, having living children correlated with lower distress rates across all measures. This study stands among the few to examine both members of couples, revealing that "pregnancy loss is not only a clinical event but a deeply emotional one, with lasting implications for both individuals.


AI Models Revolutionise IVF Success Prediction

Researchers have demonstrated that machine learning significantly outperforms traditional age-based methods in predicting IVF pregnancy success. The international, multicentre study analysed 3,852 first autologous IVF cycles performed between 2018-2023 across six fertility centres in two countries.



The AI model incorporated multiple clinical variables, including maternal and paternal age, anti-Müllerian hormone levels, antral follicle count, sperm origin and type, and history of past failed cycles. The system achieved superior performance compared to age-only models, with an area under the curve score of 0.731 versus 0.695 and improved accuracy of 67.5% versus 65.3%.



Particularly impressive were the model's predictions at extremes: over 86% accuracy for women with less than 20% chance of pregnancy and nearly 78% accuracy for those with greater than 80% chance. While maternal age remained the top predictor for first transfers, subsequent transfers showed ovarian reserve markers becoming more influential.


French Study Exposes Miscarriage Reporting Gaps

Marie-Caroline Compans from the Sexual and Reproductive Health and Rights Unit at Institut national d'études démographiques in Aubervilliers, France, presented research highlighting significant challenges in accurately measuring miscarriage prevalence. The comprehensive study drew on 13,632,246 medical records for pregnancies, FECOND study survey data from 2010-11 representing 7,196 pregnancies, and 50 in-depth interviews about miscarriage experiences.



Hospital-managed miscarriages declined from 6.9% of clinically recognised pregnancies in 2009 to 5.1% in 2023, according to the French National Health Data System. Including primary care data, rates ranged from 9.9% in 2013 to 8.9% in 2023, still considerably lower than the 14.0% miscarriage rate reported in the FECOND national survey.



This discrepancy suggests many miscarriages remain unreported in medical records, particularly those managed outside hospitals. The research confirmed maternal age and previous miscarriages as major risk factors while finding no strong links between miscarriage and socio-economic status.


Failed FET Does Not Predict Future Failure

A retrospective cohort study examining 2,385 women who underwent their first two single embryo frozen embryo transfers (FETs) between 2017–2021 provides reassuring evidence for fertility patients. The research demonstrated that prior failed FET, whether due to biochemical pregnancy loss, clinical pregnancy loss, or implantation failure, does not increase the risk of another pregnancy loss in subsequent FET.



Second FET outcomes were statistically similar across all groups regardless of first transfer results. Live birth rates in the second FET showed no significant difference across groups, with results remaining consistent after accounting for age, embryo quality, BMI, endometrial thickness, and hormonal levels.


2S/LGBTQIA+ Couples Show Resilience Despite Barriers

Research examining 345 couples (80 2S/LGBTQIA+ and 265 mixed-sex/gender) recruited from Canada and the USA between November 2019-April 2024 revealed important insights into fertility care experiences for diverse populations. While 20% of medically assisted reproduction-seeking couples identify as 2S/LGBTQIA+, fertility care remains rooted in a medicalised, cisgender framework.



Mixed-sex/gender couples demonstrated higher depressive symptoms (F[1, 205.347]=7.123; p=0.008; d=0.34), while 2S/LGBTQIA+ couples reported greater relationship satisfaction (F[1, 212.442]=8.288; p=0.004; d=–0.39) and more frequent use of dyadic coping strategies (F[1, 206.457]=5.929; p=0.016; d=–0.35).



Despite facing barriers including heteronormativity, financial strain, and microaggressions from healthcare providers, 2S/LGBTQIA+ couples showed resilience through strong relational bonds and robust social support networks.


T'easy AI Platform Transforms Sperm Detection

Researchers from UZ Brussel, Belgium, in collaboration with Robovision AI, Ghent, Belgium, introduced T'easy, an innovative AI-driven platform revolutionising sperm identification in testicular tissue samples. The system was trained on 5,373 annotated images and more than 13,000 labelled spermatozoa.



In initial testing, T'easy achieved 95.0% recall and 94.8% precision. In clinical samples, the system identified over 98% of sperm cells with fewer false positives and negatives than human operators, completing analysis in just 10 minutes compared to 24 minutes required by experienced embryologists.


Lactobacillus Species Show Varying Protective Effects

A large-scale retrospective study from Igenomix Vitrolife Group, Valencia, Spain, analysed 7,795 endometrial biopsies, investigating Lactobacillus species presence and their relationship to 26 potential reproductive tract pathogens. The research revealed significant variations between species.



Lactobacillus crispatus was associated with lower pathogen prevalence at 11.9%, while Lactobacillus gasseri showed the opposite trend, with nearly half (45.8%) of samples testing positive for at least one pathogen. Lactobacillus iners and Lactobacillus jensenii showed intermediate pathogen rates of 28.7% and 24.2%, respectively.


PGT-A Reduces Time to Pregnancy for Older Women

A multinational study across private fertility networks analysed 4,763 patients aged ≥35 years undergoing their first IVF/intracytoplasmic sperm injection cycle. Using propensity score matching, researchers compared 1,440 patients who underwent preimplantation genetic testing for aneuploidy (PGT-A) with 1,440 who did not.



While cumulative live birth rates remained comparable (30.1% with PGT-A versus 32.4% without), the live birth rate per embryo transfer was significantly higher in the PGT-A group (44.2% versus 29.1%; adjusted odds ratio: 2.15; 95% CI: 1.78–2.61). Crucially, PGT-A provided significant time-to-pregnancy advantages specifically for women aged ≥39, with notably shorter time to live birth (adjusted hazard ratio: 2.53; 95% CI: 1.56–4.12).



These ESHRE 2025 findings collectively represent substantial progress in reproductive medicine, offering enhanced treatment precision, improved patient support frameworks, and technological innovations that promise to transform fertility care delivery worldwide.

85 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.

ART

1 min read

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.

ART

1 min read

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.

ART

1 min read

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.

ART

1 min read

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.

ART

1 min read

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.

ART

1 min read

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address